Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biochemical characterization of recombinant factor IX

M Bond1, M Jankowski, H Patel

  • 1Genetics Institute, Inc, Andover, MA 01810, USA.

Seminars in Hematology
|June 13, 1998
PubMed
Summary

Recombinant human factor IX (rFIX) closely mimics plasma-derived factor IX (pdFIX) in structure and function. This advanced rFIX exhibits high purity and specific activity, meeting rigorous product release specifications for therapeutic use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to correspondence from McCarthy et al. regarding maternal sepsis screening and the role of the neutrophil-to-lymphocyte ratio.

International journal of obstetric anesthesia·2025
Same author

Maternal physiological parameters and routine laboratory tests to screen for maternal sepsis: an observational cohort study.

International journal of obstetric anesthesia·2025
Same author

Giant Cell Arteritis - Who to Refer to?

The West Indian medical journal·2017
Same author

RNA-interference-mediated downregulation of Pin1 suppresses tumorigenicity of malignant melanoma A375 cells.

Neoplasma·2012
Same author

Meta-analysis confirms that a common G/C variant in the pre-miR-146a gene contributes to cancer susceptibility and that ethnicity, gender and smoking status are risk factors.

Genetics and molecular research : GMR·2012
Same author

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

Area of Science:

  • Biochemistry
  • Protein Engineering
  • Molecular Biology

Background:

  • Mature human factor IX is a complex glycoprotein essential for blood coagulation.
  • Recombinant protein production offers a potential alternative to plasma-derived therapies.
  • Chinese hamster ovary (CHO) cell lines are widely used for producing therapeutic glycoproteins.

Purpose of the Study:

  • To characterize a novel recombinant form of human factor IX (rFIX).
  • To confirm that rFIX possesses structural and functional similarities to plasma-derived factor IX (pdFIX).
  • To assess the purity and specific activity of the rFIX product.

Main Methods:

  • Biochemical and biophysical characterization techniques were employed.
  • Analysis included assessment of posttranslational modifications.

Related Experiment Videos

  • Structural integrity (primary, secondary, tertiary) and specific activity were evaluated.

    • Main Results:

    • rFIX demonstrated comparable posttranslational modifications to pdFIX.
    • The primary, secondary, and tertiary structures of rFIX were found to be similar to pdFIX.
    • High purity and a specific activity of ≥200 IU/mg were confirmed for rFIX.

    Conclusions:

    • The recombinant human factor IX (rFIX) produced is structurally and functionally analogous to plasma-derived factor IX (pdFIX).
    • The characterized rFIX meets stringent purity and activity specifications, indicating its suitability for therapeutic applications.